Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may ...

Following President Trump’s announcement on Monday of an executive order to cut prescription drug prices, experts share some of the most expensive medications.

There are many problems with the plan. It ignores the fact, for instance, that generic drugs, which make up 90% of ...

President Donald Trump has issued a new executive order giving pharmaceutical companies a 30-day window to voluntarily lower ...

Leap Therapeutics is laying off half of its staff as the company narrows the focus of its lead cancer drug against the ...

President Donald Trump on Monday signed a sweeping executive order setting a 30-day deadline for drugmakers to electively ...

Discover Coherus BioSciences' strategic shift to oncology with Q1 2025 insights on LOQTORZI growth, pipeline progress, and revenue projections up to $200M.

HELSINKI, May 13, 2025 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (Tiltbio), a clinical-stage biotechnology company developing intravenously delivered cancer immunotherapies, announces it has raised USD ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...